Clinical Significance:
Inhibin is a polypeptide hormone secreted by grandulosa cells of the ovary in the female and sertoli cells of the testes in the male. It selectively suppresses the secretion of pituitary Follicle Stimulating Hormone (FSH) and also has local paracrine actions in the gonads. The fully processed form of the molecule consists of two discrete chains (alpha and beta), linked by disulphide bridges.
Inhibin A consists of an alpha subunit and a beta-A subunit. During pregnancy the major site of production of Inhibin A is the placenta. The role of this molecule in pregnancy is not certain, but recent findings that elevated Inhibin A levels are a maternal marker for fetal Down's Syndrome suggest a possible practical application for the assay when used in combination with other markers (Ref. 1, 2, 3, 4). In addition, Inhibin A levels appear to be useful in investigating its role in human reproductive physiology (Ref. 5, 6, 7, 8) and in the monitoring of patients with granulosa cell tumors of the ovary (Ref. 9).
Inhibin B, composed of an alpha and beta-B (bB) subunit, is also made in females and is a major circulating Inhibin in males.
Reference Range:
I. Normal postmenopausal women: Less than 5 pg/ml
II. Normal women in luteal phase: Less than 150 pg/ml
III. Hyperovulated women: Less than 1200 pg/ml
IV. Normal Male: Less than 80 pg/ml
Procedure:
Inhibin A is measured by direct immunoassay that is specific for dimeric Inhibin A levels in human female serum/plasma.
Patient Requirements:
Patient should not be on any Steroid, ACTH, Gonadotropin, or Estrogen medications, if possible, for at least 48 hours prior to collection of specimen.
Specimen Collection:
3 ml serum or EDTA plasma should be collected and separated as soon as possible. Freeze specimen immediately after separation., Minimum specimen size is 1 ml. Storage stability at least 2 months at - 20o C.
Special Specimens:
For tumor/tissue and various fluids (i.e. CSF, peritoneal, synovial, etc.) contact the Institute for requirements and special handling.
Shipping Instructions:
Ship specimens frozen in dry ice.
References:
1.Wallace, E.M., Grant, V.E., Swanson, I.A. and Groome, N.P. (1955) Evaluation of maternal serum dimeric Inhibin A as a first-trimester marker of Down's Syndrome. Prenatal Diagnosis. 15: 359-362.
2.Cuckel, H.S. , Holding, S., JOnes, R., Wallace, E.M. and Groome, N.P. (1995). Maternal Serum Dimeric Inhibin A in second trimester Down's Syndrome pregnancies. Prenatal Diagnosis 15: 385-392.
3. Canick, J.A., Lambert-Messerlian, G.M., Palomaki, G.E., Schneyer, A.L., Tumber, M.B., Knight, G.J. and Haddow, J.E. (1994) Maternal Serum Dimeric Inhibin is elevated in Down's Syndrome pregnancy. American J. Human Genetics 55: Abstract 37.
4. Wallace, E.M., Grant, V.E., Swanson, I.A., McNeilly, A.S., Ashby, J.P. and Groome, N.P. (1995). Second trimester screening for Down's Syndrome using Inhibin A. J. Endocrinol. 144: 134 (March issue supplement).
5. Groome, N.A., Illingworth, P. J., O'Brien, M., Cooke, I., Ganeson, T.S., Baird, D.T., and McNeilly, A. (1994). Detection of Dimeric inhibin throught the human menstrual cycle by two site immunoassay. Clin. Endocrinol. 40: 717-723.
6. Lambert-Messerlian, G., Hall, J.E., Sluss, P., Taylor, A.L., Martin, K.A., Groome, N.P., Crowley, W.F. and Schneyer, A. (1994). Relatively low levels of Dimeric Inhibin circulate in men and women. J. Clin. Endocrinol. Metab. 79: 45-50.
7. Muttukrishna, S., Fowler, P.A., Groome, N.P., Mitchell, G.C., Robertson, W.R. and Knight, P.G. (1994). Serum concentrations of Dimeric Inhibin during the spontaneous human menstrual cycle and after treatment with exogenous gonadotrophin. Human Reproduction 9: 1634-1642.
8. Muttukrishna, S., George, L., Fowler, P.A., Groome, N.P. and Knight, P.G. (1995). Measurement of serum concentrations of Inhibin A alpha- bA dimer during human pregnancy. Clinical Endocrinol. 42: 391-397.
9. Cooke, I., O'Brien, M., Charmock, F.M., Groome, N.P., and Ganesan, T.S. (1995). Inhibin as a marker for ovarian cancer. British Journal of Cancer 71: 1046-1050.
Clinical Significance:
Inhibin is a 58,000 molecular weight peptide comprised of two subunits. Inhibin has a strong and selective inhibitory effect of the secretion of Follicle Stimulating Hormone. It is in the same family as the Activins, Transforming Growth Factor-b, and Mullerian Inhibiting Substance. Inhibin B is secreted by the Sertoli cells in the male and granulosa cells in the follicular phase and by the corpus luteum in the luteal phase. Inhibin has two major actions: low-level inhibition of Follicle Stimulating Hormone secretion and high-level degradation of Follicle Stimulating Hormone and Luteinizing Hormone stores. Inhibin B levels are influenced by Vasoactive Intestinal Polypeptide, Growth Factors, Insulin and Somatomedin C.
Reference Range:
See attached reference ranges female and male.
Procedure:
Inhibin B is measured by a direct solid phase sandwish Elisa. Prior to ELISA patient specimens are pre-treated with detergent and heated to 100 C. It is further exposed to hydrogen peroxide (H2 O2) which enhances specificity and sensitivity. The procedure includes several in-house modifications that excludes the inclusion of the free forms of alpha inhibin that is usually present in human specimens.
Patient Requirements:
Patient should not be on any Steroid, ACTH, Gonadotropin, or Estrogen medications, if possible, for at least 48 hours prior to collection of specimen.
Specimen Collection:
3 ml serum should be collected and separated as soon as possible. Freeze specimen immediately after separation., Minimum specimen size is 1 ml.
Special Specimens:
For tumor/tissue and various fluids (i.e. CSF, peritoneal, synovial, etc.) contact the Institute for requirements and special handling.
Shipping Instructions:
Ship specimens frozen in dry ice.
References:
1. MJ Sinosich, S Siefn A Zakher, N Ling, DM Saunders, Z Rosenwaks, and GD Hodgen. Radioimmunoassay of Inhibin Based on Synthetic Human a-Chain Peptide. Clinical Chemistry 37: 40 - 46, 1991.
2. RI McLachlan, DM Robertson, DM deKretser, and HG Burger. Advances in the Physiology of Inhibin and Inhibin-Related Peptides. Clincial Endocrinology 29: 77-114, 1988.
3. S.D. Mahale, et. al., International Journal of Peptide and Protein Research 42: 132, 1993.
4. S-Y Ying. Inhibins, Activins, and Follistatins: Gonadal Proteins Modulating the Secretion of Follicle-Stimulating Hormone. Endocrine Reviews 9: 267-293,1988.
Clinical Significance:
Insulin is a 51 amino acid peptide comprised of two subchains joined by disulfide bridges. Insulin is derived from ProInsulin by metabolism releasing an inactive peptide, Insulin and C-Peptide (Connecting Peptide). The ingestion of carbohy-drates provides the necessary stimulus to release Insulin from the B-Cells of the pancreas. The primary action of Insulin is the suppression of elevated blood glucose levels achieved by stimulating the uptake of glucose by Insulin-sensitive target tissues including the liver, muscle and adipose tissues. A deficiency in Insulin secretion is one of the signs of Diabetes Mellitus Type I. Insulin levels range from low to normal to elevated in Type II diabetics. Insulin levels are greatly increased in patients with Insulinoma which can lead to hypoglycemia. Hyperinsulinemia has been found in patients with Cirrhosis, Acanthosis Nigricans, and Insulin resistant syndromes. Normally Insulin is inversely related to androgen concentration but many women with hirsutism, particularly Polycystic Ovarian Disease patients, experience Insulin resistance and elevated Insulin levels. Insulin release is strongly suppressed by Somatostatin.
Reference Range:
4 - 24 uU/ml
Procedure:
Insulin is measured by direct radioimmunoassay.
Patient Preparation:
Patient should be fasting 10 - 12 hours prior to collection of specimen. Patient should not be on any medications, if possible, that influence Insulin production or secretion.
Specimen Collection:
3 ml serum or EDTA plasma should be collected and separated as soon as possible. Freeze specimen immediately after separation. Minimum specimen size is 1 ml.
Special Specimens:
For tumor/tissue and various fluids (i.e. CSF, peritoneal, synovial, etc.) contact the Institute for requirements and special handling.
Shipping Instructions:
Ship specimens frozen in dry ice.
References:
1. RA Wild, D Applebaum-Bowden, LM Demers, M Bartholomew, JR Landis, WR Hazzard, and RJ Santen. Lipoprotein Lipids in Women with Androgen Excess: Independent Associations with Increased Insulin and Androgen. Clinical Chemistry 36: 283-289, 1990.
2. GM Argoud, DS Schade and RP Eaton. Insulin Suppresses Its Own Secretion in Vivo. Diabetes 36: 959-962, 1987.
Test performed on a research basis only.
* Test available on a research basis only. Contact ISI for details.
Clinical Significance:
The Interleukins belong to the family termed cytokines. They are peptides used by immune and inflammatory cells to communicate and control cell operations. The cytokines have some similar actions to the Growth Factors but Growth Factors regulate proliferation of non-immune cells. Interleukin 1a is a 17,500 molecular weight peptide derived primarily from macrophages, fibroblasts, endothelial cells, and B cells. The major target cells are T and B cells, Fibroblasts, and Hepatocytes. Interleukin 1a shares a receptor with Interleukin 1b although they are significantly different structurally. Interleukin 1a promotes antigen specific immune responses, inflammation, Prostaglandin secretion, Colony Stimulating Factors, proteoglycanase, collagenase, and gelatinase activity, and release of Interleukin 2 from T cells. Levels are stimulated by liposaccharide, endotoxins, inflammatory agents, lectin, Tumor Necrosis Factor, and Interferons. Levels are suppressed by Corticosteroids, Prostaglandin E2, and suppressant lymphocytes.
Reference Range:
25 - 150 pg/ml
Procedure:
Interleukin 1a is measured by direct radioimmunoassay/enzyme immunoassay.
Patient Preparation:
Patient should not be on any Corticosteroids, anti-inflammatory medications or pain killers, if possible, for at least 48 hours prior to collection of specimen.
Specimen Collection:
3 ml serum or EDTA plasma should be collected and separated as soon as possible. Freeze specimen immediately after separation. Minimum specimen size is 1 ml.
Special Specimens:
For tumor/tissue and various fluids (i.e. CSF, peritoneal, synovial, etc.) contact the Institute for requirements and special handling.
Shipping Instructions:
Ship specimens frozen in dry ice.
References:
1. JT Whicher and SW Evans. Cytokines in Disease. Clinical Chemistry 36: 1269-1281, 1990.
2. MP Bevilacqua, JS Pober, GR Majeau, W Fiers, RS Cotran, and MA Gimbrone. Recombinant Tumor Necrosis Factor Induced Pro-Coagulant Activity in Cultured Human Vascular Endothelium: Characterization and Comparison with Action of Interleukin-1. Proceedings of the National Academy of Science 83: 4533-4537, 1986.
Clinical Significance:
The Interleukins belong to the family termed cytokines. They are peptides used by immune and inflammatory cells to communicate and control cell operations. The cytokines have some similar actions to the Growth Factors but Growth Factors regulate proliferation of non-immune cells. Interleukin 1b is a 17,500 molecular weight peptide derived primarily from macrophages, fibroblasts, endothelial cells, and B cells. The major target cells are T and B cells, Fibroblasts, and Hepatocytes and it has pyrogenic activity. Interleukin 1b shares a receptor with Interleukin 1a although they are significantly different structurally. Interleukin 1b promotes antigen specific immune responses, inflammation, secretion, Colony Stimulating Factors, proteoglycanase, collagenase, and gelatinase activity, acute phase response, and cartilage resorption. Interleukin 1b increases accumulation of cell-associated and extracellular arachadonic acid, and induces release of Interleukin 6.
Reference Range:
Up to 150 pg/ml
Procedure:
Interleukin 1b is measured by direct radioimmunoassay/enzyme immunoassay.
Patient Preparation:
Patient should not be on any Corticosteroids, anti-inflammatory medications or pain killers, if possible, for at least 48 hours prior to collection of specimen.
Specimen Collection:
3 ml serum or EDTA plasma should be collected and separated as soon as possible. Freeze specimen immediately after separation. Minimum specimen size is 1 ml.
Special Specimens:
For tumor/tissue and various fluids (i.e. CSF, peritoneal, synovial, etc.) contact the Institute for requirements and special handling.
Shipping Instructions:
Ship specimens frozen in dry ice.
References:
1. JT Whicher and SW Evans. Cytokines in Disease. Clinical Chemistry 36: 1269-1281, 1990.
2. MP Bevilacqua, JS Pober, GR Majeau, W Fiers, RS Cotran, and MA Gimbrone. Recombinant Tumor Necrosis Factor Induced Pro-Coagulant Activity in Cultured Human Vascular Endothelium: Characterization and Comparison with Action of Interleukin-1. Proceedings of the National Academy of Science 83: 4533-4537, 1986.
Clinical Significance:
The Interleukins belong to the family termed cytokines. They are peptides used by immune and inflammatory cells to communicate and control cell operations. The cytokines have some similar actions to the Growth Factors but Growth Factors regulate proliferation of non-immune cells. Interleukin 2 is a 15,000 molecular weight glycoprotein originally called T Cell Growth Factor. It is released primarily by activated T Cells. Its target cells include T and B cells, Natural Killer Cells, and Lymphokine-activated Killer Cells. Interleukin 2 increases alloantigen responses and improves recovery of immune function. It also induces production of other lymphokines including Tumor Necrosis Factor, g Interferon, and Interleukin 6. It is bound to specific Interleukin 2 receptors located on activated T cells, resting and activated B cells, macrophages, and mast cells.
Reference Range:
Up to 31.3 pg/ml
Procedure:
Interleukin 2 is measured by direct radioimmunoassay/enzyme immunoassay.
Patient Preparation:
Patient should not be on any Corticosteroids, anti-inflammatory medications or pain killers, if possible, for at least 48 hours prior to collection of specimen.
Specimen Collection:
3 ml serum or EDTA plasma should be collected and separated as soon as possible. Freeze specimen immediately after separation. Minimum specimen size is 1 ml.
Special Specimens:
For tumor/tissue and various fluids (i.e. CSF, peritoneal, synovial, etc.) contact the Institute for requirements and special handling.
Shipping Instructions:
Ship specimens frozen in dry ice.
References:
1. JT Whicher and SW Evans. Cytokines in Disease. Clinical Chemistry 36: 1269-1281, 1990.
2. CM Huang, RJ Elin, M Ruddel, C Silva, MT Lotze, and SA Rosenberg. Changes in Laboratory Results for Cancer Patients Treated with Interleukin-2. Clinical Chemistry 36: 431-434, 1990.
Clinical Significance:
The Interleukins belong to the family termed cytokines. They are peptides used by immune and inflammatory cells to communicate and control cell operations. The cytokines have some similar actions to the Growth Factors but Growth Factors regulate proliferation of non-immune cells. Interleukin 3 is a 20,000 - 26,000 molecular weight glycoprotein originally called Multi-Colony Stimulating Factor. It is released primarily by activated T Cells. Its primary target cells are early hemopoietic cells. Interleukin 3 also stimulates proliferation of macrophages, neutrophils, eosinophils, megakaryocytes, and mast cells. Interleukin 3 activates pluripotent stem cells giving rise to a wide range of cell types. It also induces 20a-Steroid Dehydrogenase in T cells and Leukotriene C4. It works in conjunction with Interleukin 6 to hasten the emergence of blast cell colony-forming cells.
Reference Range:
Up to 5.0 pg/ml
Procedure:
Interleukin 3 is measured by direct radioimmunoassay/enzyme immunoassay.
Patient Preparation:
Patient should not be on any Corticosteroids, anti-inflammatory medications or pain killers, if possible, for at least 48 hours prior to collection of specimen.
Specimen Collection:
3 ml serum or EDTA plasma should be collected and separated as soon as possible. Freeze specimen immediately after separation. Minimum specimen size is 1 ml.
Special Specimens:
For tumor/tissue and various fluids (i.e. CSF, peritoneal, synovial, etc.) contact the Institute for requirements and special handling.
Shipping Instructions:
Ship specimens frozen in dry ice.
References:
1. JT Whicher and SW Evans. Cytokines in Disease. Clinical Chemistry 36: 1269-1281, 1990.
2. JN Ihle. The Molecular and Cellular Biology of Interleukin-3. Yearbook of Immunology 5: 59-102, 1989.
Clinical Significance:
The Interleukins belong to the family termed cytokines. They are peptides used by immune and inflammatory cells to communicate and control cell operations. The cytokines have some similar actions to the Growth Factors but Growth Factors regulate proliferation of non-immune cells. Interleukin 4 is a 20,000 molecular weight glycoprotein originally called T Cell Growth Factor along with Interleukin 2. It is released primarily by activated T Cells and mast cells. Its primary target cells are T and B cells, macrophage/monocytes, and mast cells. Interleukin 4 activates B cell differentiation and immunoglobulins prior to action of Interleukin 6. It is also a co-stimulator along with anti-immunoglobulin antibodies of B cell proliferation. Interleukin 4 is bound to receptors located on activated T cells, resting and activated B cells, macrophages, and mast cells.
Reference Range:
200 - 1800 pg/ml
Procedure:
Interleukin 4 is measured by direct radioimmunoassay/enzyme immunoassay.
Patient Preparation:
Patient should not be on any Corticosteroids, anti-inflammatory medications or pain killers, if possible, for at least 48 hours prior to collection of specimen.
Specimen Collection:
3 ml serum or EDTA plasma should be collected and separated as soon as possible. Freeze specimen immediately after separation. Minimum specimen size is 1 ml.
Special Specimens:
For tumor/tissue and various fluids (i.e. CSF, peritoneal, synovial, etc.) contact the Institute for requirements and special handling.
Shipping Instructions:
Ship specimens frozen in dry ice.
References:
1. JT Whicher and SW Evans. Cytokines in Disease. Clinical Chemistry 36: 1269-1281, 1990.
2. JP Galizzi, B Castle, and O Djossou. Purification of a 130K Da T-cell Glycoprotein that Binds Human Interleukin-4 with High Affinity. Journal of Biological Chemistry 265: 439-44, 1990.
Clinical Significance:
The Interleukins belong to the family termed cytokines. They are peptides used by immune and inflammatory cells to communicate and control cell operations. The cytokines have some similar actions to the Growth Factors but Growth Factors regulate proliferation of non-immune cells. Interleukin 5 is a 50,000-60,000 molecular weight glycoprotein originally called T Cell Replacing Factor. It is released primarily by activated T Cells. Its primary target cells are B cells and eosinophils. Interleukin 5 activates B cell differentiation. Its actions are similar to Interleukin 3. Interleukin 5 primes basophils for agonist-induced generation of Leukotriene C4. It is stimulated by Interleukin 2. Interleukin 5 stimulates growth and differentiation of eosinophil progenitor without influencing cells committed to neutrophils, basophils, or monocytes. It enhances responsiveness of eosinophils inducing polarization, shape change, chemotaxis, cytotoxity, oxygen radical release and prolongs survival.
Reference Range:
Up to 10 pg/ml
Procedure:
Interleukin 5 is measured by direct radioimmunoassay/enzyme immunoassay.
Patient Preparation:
Patient should not be on any Corticosteroids, anti-inflammatory medications or pain killers, if possible, for at least 48 hours prior to collection of specimen.
Specimen Collection:
3 ml serum or EDTA plasma should be collected and separated as soon as possible. Freeze specimen immediately after separation. Minimum specimen size is 1 ml.
Special Specimens:
For tumor/tissue and various fluids (i.e. CSF, peritoneal, synovial, etc.) contact the Institute for requirements and special handling.
Shipping Instructions:
Ship specimens frozen in dry ice.
References:
1. JT Whicher and SW Evans. Cytokines in Disease. Clinical Chemistry 36: 1269-1281, 1990.
2. SC Bischoff, T Brunner, AL DeWeck, and LA Dahinden. Interleukin-5 Modifies Histamine Release and Leukotriene Generation by Human Basophils in Response to Diverse Agonists. Journal of Experimental Medicine 18: 1577-1582, 1990.
Clinical Significance:
The Interleukins belong to the family termed cytokines. They are peptides used by immune and inflammatory cells to communicate and control cell operations. The cytokines have some similar actions to the Growth Factors but Growth Factors regulate proliferation of non-immune cells. Interleukin 6 is a 25,000 molecular weight glycoprotein produced primarily in macrophages, T cells, fibroblasts and endothelial cells. Its primary target cells are T and B cells and neutrophils. Its main actions are involvement in terminal differentiation of B cells to antibody secreting plasma cells, activation of T cells and stimulation of hepatocyte production of acute phase proteins. Interleukin stimulates Prolactin, Growth Hormone, Luteinizing Hormone, Follicle Stimulating Hormone and ACTH. Release is stimulated by Interleukin 1a and b, Vasoactive Intestinal Polypeptide, and Prostaglandin E2. Release is not affected by aspirin or indomethacin. Levels are elevated in multiple myeloma, rheumatoid arthritis, systemic lupus erythematosus, meningococcus meningitis and infectious peritonitis.
Reference Range:
2 - 29 pg/ml
Procedure:
Interleukin 6 is measured by direct radioimmunoassay/enzyme immunoassay.
Patient Preparation:
Patient should not be on any Corticosteroids, anti-inflammatory medications or pain killers, if possible, for at least 48 hours prior to collection of specimen.
Specimen Collection:
3 ml serum or EDTA plasma should be collected and separated as soon as possible. Freeze specimen immediately after separation. Minimum specimen size is 1 ml.
Special Specimens:
For tumor/tissue and various fluids (i.e. CSF, peritoneal, synovial, etc.) contact the Institute for requirements and special handling.
Shipping Instructions:
Ship specimens frozen in dry ice.
References:
1. JT Whicher and SW Evans. Cytokines in Disease. Clinical Chemistry 36: 1269-1281, 1990.
2. BL Spangelo, WD Jarvis, AM Judd, and RM MacLeod. Induction of Interleukin-6 Release by Interleukin-1 in Rat Anterior Pituitary Cells in vitro: Evidence for an Eicosanoid Dependent Mechanism. Endocrinology 129: 2886-2894, 1991.
Clinical Significance:
The Interleukins belong to the family termed cytokines. They are peptides used by immune and inflammatory cells to communicate and control cell operations. The cytokines have some similar actions to the Growth Factors but Growth Factors regulate proliferation of non-immune cells. Interleukin 7 is a 25,000 molecular weight glycoprotein produced primarily in bone marrow stromal cells. Its primary target cells are B cells. Interleukin 7 supports long term culture of B cells. Interleukin 7 plays an important role in maintenance of a population of pre B lymphocytes although it does not stimulate differention of pre B cells to B cells. Interleukin 7 also activates myeloid cell proliferation and differentiation.
Reference Range:
Up to 8 pg/ml
Procedure:
Interleukin 7 is measured by direct radioimmunoassay/enzyme immunoassay.
Patient Preparation:
Patient should not be on any Corticosteroids, anti-inflammatory medications or pain killers, if possible, for at least 48 hours prior to collection of specimen.
Specimen Collection:
3 ml serum or EDTA plasma should be collected and separated as soon as possible. Freeze specimen immediately after separation. Minimum specimen size is 1 ml.
Special Specimens:
For tumor/tissue and various fluids (i.e. CSF, peritoneal, synovial, etc.) contact the Institute for requirements and special handling.
Shipping Instructions:
Ship specimens frozen in dry ice.
References:
1. JT Whicher and SW Evans. Cytokines in Disease. Clinical Chemistry 36: 1269-1281, 1990.
2. P Hunt, D Robertson, D Weiss, D Rennick, F Lee, and ON Witte. A Single Marrow-Derived Stromal Cell Type Supports the in vitro Growth of Early Lymphoid and Myeloid Cells. Cell 48: 997-1007, 1987.
Clinical Significance:
The Interleukins belong to the family termed cytokines. They are peptides used by immune and inflammatory cells to communicate and control cell operations. The cytokines have some similar actions to the Growth Factors but Growth Factors regulate proliferation of non-immune cells. Interleukin 8 is a 6,000 - 8000 molecular weight glycoprotein produced primarily by macrophages and monocytes. Its primary target cells are neutrophils. Interleukin 8 is a chemotactic agent for monocytes and neutrophils. Interleukin 8 causes oxygen radical and enzyme release by neutrophils and mobilizes products into circulation. Interleukin 8 is stimulated by Interleukin 1 and Tumor Necrosis Factor.
Reference Range:
10 - 80 pg/ml
Procedure:
Interleukin 8 is measured by direct radioimmunoassay/enzyme immunoassay.
Patient Preparation:
Patient should not be on any Corticosteroids, anti-inflammatory medications or pain killers, if possible, for at least 48 hours prior to collection of specimen.
Specimen Collection:
3 ml serum or EDTA plasma should be collected and separated as soon as possible. Freeze specimen immediately after separation. Minimum specimen size is 1 ml.
Special Specimens:
For tumor/tissue and various fluids (i.e. CSF, peritoneal, synovial, etc.) contact the Institute for requirements and special handling.
Shipping Instructions:
Ship specimens frozen in dry ice.
References:
1. JT Whicher and SW Evans. Cytokines in Disease. Clinical Chemistry 36: 1269-1281, 1990.
2. K Matsushima, JJ Oppenheim. Interleukin-8 and Macrophage Colony Stimulating Factor: Novel Inflammatory Cytokines Inducible by Interleukin I and Tumor Necrosis Factor. Cytokine 1: 2 - 13, 1989.
Clinical Significance:
The Interleukins belong to the family termed cytokines. They are peptides used by immune and inflammatory cells to communicate and control cell operations. The cytokines have some similar actions to the Growth Factors but Growth Factors regulate proliferation of non-immune cells.
Reference Range:
Up to 15.5 pg/ml
Procedure:
Interleukin 10 is measured by direct radioimmunoassay/enzyme immunoassay.
Patient Preparation:
Patient should not be on any Corticosteroids, anti-inflammatory medications or pain killers, if possible, for at least 48 hours prior to collection of specimen.
Specimen Collection:
3 ml serum or EDTA plasma should be collected and separated as soon as possible. Freeze specimen immediately after separation. Minimum specimen size is 1 ml.
Special Specimens:
For tumor/tissue and various fluids (i.e. CSF, peritoneal, synovial, etc.) contact the Institute for requirements and special handling.
Shipping Instructions:
Ship specimens frozen in dry ice.
References:
1. JT Whicher and SW Evans. Cytokines in Disease. Clinical Chemistry 36: 1269-1281, 1990.
2. K Matsushima, JJ Oppenheim. Interleukin-8 and Macrophage Colony Stimulating Factor: Novel Inflammatory Cytokines Inducible by Interleukin I and Tumor Necrosis Factor. Cytokine 1: 2 - 13, 1989.
Clinical Significance:
The Interleukins belong to the family termed cytokines. They are peptides used by immune and inflammatory cells to communicate and control cell operations. The cytokines have some similar actions to the Growth Factors but Growth Factors regulate proliferation of non-immune cells.
Reference Range:
Up to 200 pg/ml
Procedure:
Interleukin 12 is measured by direct radioimmunoassay/enzyme immunoassay.
Patient Preparation:
Patient should not be on any Corticosteroids, anti-inflammatory medications or pain killers, if possible, for at least 48 hours prior to collection of specimen.
Specimen Collection:
3 ml serum or EDTA plasma should be collected and separated as soon as possible. Freeze specimen immediately after separation. Minimum specimen size is 1 ml.
Special Specimens:
For tumor/tissue and various fluids (i.e. CSF, peritoneal, synovial, etc.) contact the Institute for requirements and special handling.
Shipping Instructions:
Ship specimens frozen in dry ice.
References:
1. JT Whicher and SW Evans. Cytokines in Disease. Clinical Chemistry 36: 1269-1281, 1990.
2. K Matsushima, JJ Oppenheim. Interleukin-8 and Macrophage Colony Stimulating Factor: Novel Inflammatory Cytokines Inducible by Interleukin I and Tumor Necrosis Factor. Cytokine 1: 2 - 13, 1989.
Clinical Significance:
The Interleukins belong to the family termed cytokines. They are peptides used by immune and inflammatory cells to communicate and control cell operations. The cytokines have some similar actions to the Growth Factors but Growth Factors regulate proliferation of non-immune cells.
Reference Range:
Non-detectable.
Procedure:
Interleukin 13 is measured by direct radioimmunoassay/enzyme immunoassay.
Patient Preparation:
Patient should not be on any Corticosteroids, anti-inflammatory medications or pain killers, if possible, for at least 48 hours prior to collection of specimen.
Specimen Collection:
3 ml serum or EDTA plasma should be collected and separated as soon as possible. Freeze specimen immediately after separation. Minimum specimen size is 1 ml.
Special Specimens:
For tumor/tissue and various fluids (i.e. CSF, peritoneal, synovial, etc.) contact the Institute for requirements and special handling.
Shipping Instructions:
Ship specimens frozen in dry ice.
References:
1. JT Whicher and SW Evans. Cytokines in Disease. Clinical Chemistry 36: 1269-1281, 1990.
2. K Matsushima, JJ Oppenheim. Interleukin-8 and Macrophage Colony Stimulating Factor: Novel Inflammatory Cytokines Inducible by Interleukin I and Tumor Necrosis Factor. Cytokine 1: 2 - 13, 1989.
* Test available on a research basis only. Contact ISI for details.
* Test available on a research basis only. Contact ISI for details.
Please e-mail us your comments and suggestions regarding these pages. Are there other syndromes or tests that you would be interested in seeing? For our general knowledge, please tell us for which purposes you are accessing this page: general information; ordering tests; research or other(please specify). Any information gathered will be used for internal research purposes only: Confidentiality will be maintained.